Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL27680958 | 0.98 | KIF11 (0.59) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3835118 | 0.93 | KIF11 (0.59) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27676286 | 0.91 | KIF11 (0.57) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27595906 | 0.91 | KIF11 (0.57) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28062215 | 0.91 | KIF11 (0.57) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5868580 | 0.91 | KIF11 (0.57) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17817860 | 0.91 | KIF11 (0.57) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3137055 | 0.88 | ESR2 (0.61) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Cyanide SCHEMBL27787964 | 0.87 | KIF11 (0.53) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Iodide SCHEMBL28747484 | 0.87 | KIF11 (0.48) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1204592-C | Probes for gas phase ion spectrometer | CIPHERGEN BIOSYSTEMS INC (US) | 2005-06-01 | — | — | CN | claimed |
| US-6682856-B1 | POWER SOURCES FOR PORTABLE ELECTRONICS COMPRISING METAL OXIDES AND INTERCALATION COMPOUND TERMINALS AND ELECTROCONDUCTIVE ACYLIC ESTERS IN OXIDATION RESISTANCE SOLVENTS AS ANOLYTES, HAVING STORAGE STABILITY, HIGH ENERGY AND VOLTAGE | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2004-01-27 | — | — | US | claimed |
| CN-1108296-C | Glucosan compound and its synthesis and use thereof | WU ZHONG (CN) | 2003-05-14 | — | — | CN | claimed |
| CN-1360732-A | Probes for gas phase ion spectrometer | CIPHERGEN BIOSYSTEMS INC (US) | 2002-07-24 | — | — | CN | claimed |
| CN-1349671-A | Nonaqueous electrolyte secondary battery | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2002-05-15 | — | — | CN | claimed |
| EP-1195833-A1 | NON-AQUEOUS ELECTROLYTE SECONDARY CELL | Matsushita Electric Industrial Co., Ltd. (JP) | 2002-04-10 | — | — | EP | claimed |
| US-12570774-B2 | Cycloolefin resin cured product having oxygen barrier properties | RIMTEC CORPORATION (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4703402-A1 | POLYMERIZABLE COMPOSITION AND MOLDED ARTICLE | RIMTEC Corporation (JP) | 2026-03-04 | — | — | EP | disclosed |
| EP-3960414-B1 | METHOD FOR PRODUCING CYCLOOLEFIN RESIN-DECORATIVE MOLDED ARTICLE | RIMTEC CORP (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-12343905-B2 | Method for producing cycloolefin resin-decorative molded article | RIMTEC CORPORATION (JP) | 2025-07-01 | — | — | US | disclosed |
| WO-2024224997-A1 | POLYMERIZABLE COMPOSITION AND MOLDED ARTICLE | RIMTEC株式会社 | 2024-10-31 | — | — | WO | disclosed |
| US-20240287234-A1 | COMPOSITE MATERIAL AND MOLDED COMPOSITE MATERIAL | RIMTEC CORPORATION (JP) | 2024-08-29 | — | — | US | disclosed |
| US-12012474-B2 | Composite material and molded composite material | RIMTEC CORPORATION (JP) | 2024-06-18 | — | — | US | disclosed |
| CN-1108296-C | Glucosan compound and its synthesis and use thereof | WU ZHONG (CN) | 2003-05-14 | — | — | CN | disclosed |
| CN-1360732-A | Probes for gas phase ion spectrometer | CIPHERGEN BIOSYSTEMS INC (US) | 2002-07-24 | — | — | CN | disclosed |
| CN-1349671-A | Nonaqueous electrolyte secondary battery | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2002-05-15 | — | — | CN | disclosed |
| EP-1195833-A1 | NON-AQUEOUS ELECTROLYTE SECONDARY CELL | Matsushita Electric Industrial Co., Ltd. (JP) | 2002-04-10 | — | — | EP | disclosed |
| CN-1269361-A | Glucosan compound and its synthesis and use thereof | WU ZHONG (CN) | 2000-10-11 | — | — | CN | disclosed |
| WO-1998000434-A1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 1998-01-08 | — | — | WO | disclosed |
| CN-1111249-A | TTTr as protective group in nucleotide synthesis | CIBA GEIGY AG (CH) | 1995-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570774-B2 | Cycloolefin resin cured product having oxygen barrier properties | HMOX1, GPX1, ALOX12 | KIF11 4463/4885KCNH2 4037/4885CYP3A4 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.